Prosensa Holding Rating Lowered to Neutral at Citigroup Inc. (RNA)
Prosensa Holding (NYSE:RNA) was downgraded by stock analysts at Citigroup Inc. from a “buy” rating to a “neutral” rating in a report issued on Monday, TheFlyOnTheWall.com reports.
Shares of Prosensa Holding (NYSE:RNA) opened at 7.14 on Monday. Prosensa Holding has a one year low of $5.65 and a one year high of $34.55. The stock has a 50-day moving average of $24.71 and a 200-day moving average of $25.16. The company’s market cap is $207.1 million.
Several other analysts have also recently commented on the stock. Analysts at Leerink Swann cut their price target on shares of Prosensa Holding (NYSE:RNA) from $35.00 to $11.00 in a research note to investors on Friday. Separately, analysts at Wedbush reiterated a “buy” rating on shares of Prosensa Holding (NYSE:RNA) in a research note to investors on Friday, September 6th. Finally, analysts at Wedbush initiated coverage on shares of Prosensa Holding (NYSE:RNA) in a research note to investors on Tuesday, July 23rd. They set an “outperform” rating and a $50.00 price target on the stock.
Prosensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (NYSE:RNA)-modulating, therapeutics for the treatment of genetic disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.